ETFs TaiMed Biologics Inc.

Equities

4147

TW0004147004

Biotechnology & Medical Research

End-of-day quote Taipei Exchange 18:00:00 2024-07-15 EDT 5-day change 1st Jan Change
85.6 TWD -0.81% Intraday chart for TaiMed Biologics Inc. +1.78% +4.39%

ETFs positioned on TaiMed Biologics Inc.

TaiMed Biologics Inc. is a Taiwan-based company principally engaged in the research and development of new medicines. The Company mainly provides ibalizumab (TMB-355) and TMB-360, which are applied in the treatment of acquired immune deficiency syndrome (AIDS), and protease inhibitor (TMB-607), which is applied as pro-drugs for AIDS. The Company's ibalizumab is a humanized monoclonal antibody, which can interfere with the penetration of the virus into the cell. Its protease inhibitor uses nanotechnology formulation for subcutaneous and/or intramuscular injections.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
85.6 TWD
Average target price
137 TWD
Spread / Average Target
+60.07%
Consensus
  1. Stock Market
  2. Equities
  3. 4147 Stock
  4. ETFs TaiMed Biologics Inc.